€456.30
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 1.110% | 0.974% | 2.840% | 43.852% | 22.777% | 170.769% | 204.281% |
| Incyte Corp. | 0.440% | 4.394% | 9.305% | 11.661% | 11.385% | -3.452% | -11.904% |
| Regeneron Pharmaceuticals Inc. | 1.730% | 1.554% | -0.710% | 50.401% | 24.564% | 102.859% | 257.982% |
| Exact Sciences | -4.920% | -3.021% | 0.943% | -51.746% | -39.107% | -56.567% | -60.751% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.
Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.
The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.
Comments
News
Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (NASDAQ: VRTX) has made it to the major leagues in the world of biotech. The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more